Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology · Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Monitoring and Long-Term Management

At a Glance

Long-term CIDP care relies on repeated strength and function measures, symptom tracking, and individualized treatment decisions. Stable patients may sometimes taper therapy with a neurologist, while rehabilitation can address residual numbness, fatigue, pain, and balance problems.

Managing CIDP is a long-term journey that involves more than just monitoring your strength. Because your own “subjective” feelings—how you feel on a specific day—can be influenced by sleep, stress, or minor illnesses, doctors use objective measurement tools to make sure your treatment is truly effective [1][2].

Measuring Your Progress

Your medical team will likely use several standardized scales to track your “functional outcomes.” These tests help move beyond “I feel okay” to “Your nerves are functioning better” [3].

  • INCAT Disability Scale: This scale measures how much your arm and leg function is limited. In some clinical trials, a change of 1 point has been used as a threshold for a “confirmed improvement” or a “relapse” [4][5].
  • I-RODS: This is a questionnaire that focuses on your ability to perform daily activities, from walking a mile to handling small objects. In specific studies, an 8-point improvement was considered a significant clinical gain [6].
  • Grip Strength: Using a device called a dynamometer, your doctor can precisely measure the strength in your hands. In some protocols, a 10% change serves as a sign of a meaningful shift [2][7].
  • MRC Sum Score: This is a manual test where the doctor checks the strength of specific muscle groups (like your shoulders, wrists, and hips) on a scale of 0 to 5 [8].

Keep in mind that these thresholds (like 1-point on INCAT or 10% on grip) are examples from study protocols, not universal rules for you to self-diagnose a relapse. Your neurologist integrates repeated measurements with your reported function. Tracking Your Symptoms at Home: It is very helpful to keep a simple daily or weekly symptom log. Note your strength, walking distance, hand function, sensation, fatigue, and any falls, along with where you are in your infusion cycle. This helps spot sustained trends rather than just isolated “bad days.”

The Question of “Weaning”

If you have been clinically stable for a long period, you and your doctor may discuss tapering—slowly reducing your dose or increasing the time between infusions to see if your disease has entered remission [9][10].

Never stop or change your treatment on your own. Abrupt steroid withdrawal can be dangerous, and immunoglobulin changes require a physician’s guidance. Tapering is a stepwise, individualized process. For example, some study protocols have reduced a dose by 25% every 12 weeks, but there is no single schedule for everyone [11]. While selected studies suggest 40% to 66% of eligible patients may be able to successfully stop treatment or stay on a lower dose, others will experience a relapse [11][10]. If you do relapse during a taper, recovery after restarting treatment is common, but it is not guaranteed or always complete [12][13].

Living with Residual Symptoms

Even when the “attack” is stopped by medication, many patients live with residual symptoms. These can be caused by axonal loss—permanent damage to the core of the nerve that occurred before treatment began [14][15].

  • Sensory Deficits: Numbness or tingling can persist. In one cohort, up to 96% of patients still had some sensory deficit even after their strength returned [16].
  • Fatigue and Pain: Chronic fatigue and neuropathic pain (burning or electric-like sensations) are common and can independently limit your daily activities more than weakness alone [17][18].
  • Imbalance: “Sensory ataxia”—a lack of coordination caused by not being able to feel your feet clearly—can lead to falls [19][20].

It is important to remember that residual numbness and fatigue do not automatically mean your treatment is failing. They can also reflect incomplete remyelination, poor sleep, medication side effects, or deconditioning. However, do not assume new symptoms are harmless—new or worsening symptoms could indicate active disease or an infusion “wear-off” that needs addressing.

The Role of Rehabilitation

Because CIDP affects your daily life, Physical Therapy (PT) and Occupational Therapy (OT) are essential [17]. A PT can help you with balance training, fall prevention, and safe exercise to maintain muscle mass without overexertion [21]. An OT can provide tools and strategies for pacing, “energy conservation,” and home modifications to help you stay independent [22][23]. Pay special attention to fall safety: use appropriate footwear, ensure good lighting and handrails in your home, and inspect your feet daily if you have reduced sensation. Working with a multidisciplinary team ensures you are managing the disease from every angle, not just through medication [9].

Common questions in this guide

How do doctors monitor CIDP over time?
Doctors combine repeated assessments of strength and daily function with your reported symptoms. Common tools include the INCAT disability scale, I-RODS questionnaire, grip-strength testing with a dynamometer, and the MRC muscle-strength score. Looking at trends over time is more useful than relying on one difficult day.
What should I record at home while living with CIDP?
A daily or weekly log can include strength, walking distance, hand function, numbness or tingling, fatigue, pain, falls, and where you are in your infusion cycle. This record can help your neurologist recognize sustained changes and distinguish a trend from a temporary bad day.
Can CIDP treatment be tapered or stopped if I feel better?
If you have been stable for a long time, your neurologist may discuss slowly reducing a dose or lengthening the time between infusions. There is no single tapering schedule, and relapse can occur, so steroids, immunoglobulin, or other treatment should never be stopped or changed without medical supervision.
How can I tell residual CIDP symptoms from active disease?
Persistent numbness, fatigue, pain, or balance problems may reflect lasting nerve damage, incomplete nerve repair, poor sleep, medication effects, or deconditioning and do not automatically mean treatment has failed. New or worsening symptoms, or symptoms that return before an infusion, can signal active disease or treatment wear-off and should be discussed with your neurologist.
Can rehabilitation help with CIDP fatigue, weakness, or balance problems?
Physical therapy can support balance training, fall prevention, safe exercise, and muscle maintenance without overexertion. Occupational therapy can help with pacing, energy conservation, daily tasks, and home modifications that support independence.
What can help CIDP-related nerve pain?
Neuropathic pain can continue even when strength improves and may limit daily activities. Ask your clinician whether a pain treatment such as gabapentin or pregabalin is appropriate for your symptoms and other medicines.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my baseline score on the INCAT and I-RODS scales, and how have those numbers changed since I started treatment?
  2. 2.If we decide to trial a dose reduction, what specific 'relapse threshold' will we use to trigger a return to my full dose?
  3. 3.How can we distinguish between my persistent sensory numbness and 'active' inflammation that might require more aggressive treatment?
  4. 4.Given my current fatigue and balance issues, can you provide a referral to a physical therapist who specializes in neuromuscular disorders?
  5. 5.Are my current pain levels high enough to warrant specific neuropathic pain medications like gabapentin or pregabalin?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial.

    Rajabally YA, Ouaja R, Kasiborski F, et al.

    Muscle & nerve 2022; (66(5)):562-567 doi:10.1002/mus.27713.

    PMID: 36057106
  2. 2

    Minimal Clinically Important Difference for the Jamar Hand Grip Dynamometer in CIDP: A Korea-UK Study.

    Min YG, Rajabally Z, Ju W, et al.

    European journal of neurology 2025; (32(8)):e70335 doi:10.1111/ene.70335.

    PMID: 40853085
  3. 3

    Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.

    Vu T, Anthony N, Alsina R, et al.

    Muscle & nerve 2021; (64(3)):351-357 doi:10.1002/mus.27345.

    PMID: 34076265
  4. 4

    Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.

    Allen JA, Lin J, Basta I, et al.

    The Lancet. Neurology 2024; (23(10)):1013-1024 doi:10.1016/S1474-4422(24)00309-0.

    PMID: 39304241
  5. 5

    Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.

    Bril V, Hadden RDM, Brannagan TH, et al.

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):436-449 doi:10.1111/jns.12573.

    PMID: 37314318
  6. 6

    Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy.

    Rajabally YA, Afzal S, Ghasemi M

    Muscle & nerve 2021; (64(1)):37-42 doi:10.1002/mus.27250.

    PMID: 33835480
  7. 7

    Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.

    Allen JA, Pasnoor M, Dimachkie MM, et al.

    Neurology 2021; (96(14)):e1876-e1886 doi:10.1212/WNL.0000000000011703.

    PMID: 33593867
  8. 8

    Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post-hoc analysis of the immunoglobulin overtreatment in CIDP trial.

    van Veen R, Wieske L, Lucke I, et al.

    Journal of the peripheral nervous system : JPNS 2022; (27(2)):144-158 doi:10.1111/jns.12497.

    PMID: 35507446
  9. 9

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  10. 10

    Safety and Cost Analysis of Immunoglobulin Cessation Trials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Koay S, Chen YC, Ransley G, et al.

    Journal of the peripheral nervous system : JPNS 2025; (30(1)):e70007 doi:10.1111/jns.70007.

    PMID: 39967344
  11. 11

    Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy.

    Markvardsen LK, Sindrup SH, Christiansen I, et al.

    Journal of neuromuscular diseases 2023; (10(5)):787-796 doi:10.3233/JND-221615.

    PMID: 37393512
  12. 12

    An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy.

    Kapoor M, Compton L, Rossor A, et al.

    Journal of the peripheral nervous system : JPNS 2021; (26(4)):461-468 doi:10.1111/jns.12470.

    PMID: 34637194
  13. 13

    Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

    van Schaik IN, Mielke O, Bril V, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2019; (6(5)):e590 doi:10.1212/NXI.0000000000000590.

    PMID: 31355323
  14. 14

    Determinants of long-term disability in chronic inflammatory demyelinating polyradiculoneuropathy: A multicenter Korea/UK study of 144 patients.

    Min YG, Jeon J, Kim SM, et al.

    European journal of neurology 2025; (32(1)):e16575 doi:10.1111/ene.16575.

    PMID: 39654304
  15. 15

    Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy.

    Al-Zuhairy A, Jakobsen J, Moldovan M, Krarup C

    Muscle & nerve 2022; (66(6)):715-722 doi:10.1002/mus.27722.

    PMID: 36217677
  16. 16

    Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.

    Bus SRM, Broers MC, Lucke IM, et al.

    Journal of neurology 2022; (269(2)):945-955 doi:10.1007/s00415-021-10677-5.

    PMID: 34173873
  17. 17

    Chronic inflammatory neuropathies and their impact on activities and participation.

    Wonink HA, Kruithof WJ, Goedee HS, Beelen A

    European journal of neurology 2023; (30(7)):1928-1936 doi:10.1111/ene.15815.

    PMID: 37038272
  18. 18

    Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Merkies IS, Kieseier BC

    European neurology 2016; (75(3-4)):199-206 doi:10.1159/000445347.

    PMID: 27077919
  19. 19

    Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.

    Devaux JJ, Miura Y, Fukami Y, et al.

    Neurology 2016; (86(9)):800-7 doi:10.1212/WNL.0000000000002418.

    PMID: 26843559
  20. 20

    Post-COVID-19 chronic inflammatory demyelinating polyneuropathy: a case report of diagnosis and management.

    Amro OW, Salah OE, Doudin AA, et al.

    Annals of medicine and surgery (2012) 2026; (88(5)):2906-2910 doi:10.1097/MS9.0000000000004827.

    PMID: 42078607
  21. 21

    Are the treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) effective and safe? - A Cochrane Overview summary with commentary.

    Oaklander AL, Gimigliano F

    NeuroRehabilitation 2019; (44(4)):609-612 doi:10.3233/NRE-189007.

    PMID: 31256085
  22. 22

    Experiences of Immunoglobulin Therapy for Those with a Confirmed Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy: A Mixed-Methods Study with a Qualitative Patient Perspective Focus.

    Hubsch A, Cashmore SJ, Mallick R, Gibbons B

    Patient preference and adherence 2025; (19()):3999-4019 doi:10.2147/PPA.S543188.

    PMID: 41409888
  23. 23

    Evaluating Grasp Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Using Dynamometers: A Comprehensive Review.

    Tsoumanis P, Chatzoglou T, Smyris TI, et al.

    Journal of clinical medicine research 2025; (17(3)):136-144 doi:10.14740/jocmr6179.

    PMID: 40115839

This page explains how CIDP may be monitored and managed over time for educational purposes and does not replace medical advice. Do not change infusions, steroids, or other treatment without guidance from your neurologist.

Get notified when new evidence is published on polyneuropathy, inflammatory demyelinating, chronic.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.